SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Mergers and acquisitions

Mergers and acquisitions

The pharmaceutical industry seems besieged on all sides, with declining R&D productivity, expiring patents on blockbuster products and relentless downward pricing pressure forcing companies to look closely at the bottom line. One affect of this onslaught has been an upsurge in the level of M&A activity as players within the industry consolidate to cut costs, expand research pipelines and lengthen geographic reach.

Biogen haemophilia spin-out to develop gene therapies and long-acting factors

04-May-2016 - The new entity will focus on a haemophilia pipeline utilising the XTEN half-life extension technology, bispecific antibodies and gene therapies.

Return to growth: Pfizer thanks Hospira and looks to biosimilars

04-May-2016 - Pfizer has attributed Hospira’s sterile injectables and biosimilar assets to its return to growth, offsetting 17 quarters of declining sales.

Lonza would add drug delivery tech through Catalent merger, analyst

14-Apr-2016 - Lonza acquiring Catalent would make “strategic sense,” according to an analyst as rumours circulate about a CMO megamerger.

Capsugel ripe to be sold or go public, investment banker

30-Mar-2016 - Rumours Capsugel owner KKR is mulling a sale or an IPO fit with the typical private equity investment cycles says expert.

Blu buy bolsters Puracap in US softgel market

29-Mar-2016 - Puracap has bought Blu Pharmaceuticals and its Puerto Rican manufacturing site and plans to double oral dose production capacity.

M&A strategy paying off for AMRI; more API acqs to come

18-Feb-2016 - Controlled substances and peptides are on AMRI’s wish list as it profits from a growth strategy which has seen six acquisitions over the past two years.

Pfizer and Allergan to mull splitting up again in 2018 say CEOs

13-Jan-2016 - The Pfizer-Allergan $160bn merger will create the world’s largest pharma company but potentially not for long, as the two CEOs discuss breaking the entity up in 2018.

Sun selling Ohio plant in post-Ranbaxy network restructure

15-Dec-2015 - Sun Pharma has announced it will divest a plant in Ohio to further consolidate manufacturing operations following its $4bn acquisition of Ranbaxy.

Pfizer-Allergan merger

‘Over 90%’ of industry thinks Pfizer will sell generics biz

30-Nov-2015 - Pfizer says it will decide in 2018 whether to split its generics and branded businesses but M&A experts are already predicting how the giant will get rid of its established...

Pfizer-Allergan combo would comprise 100+ sites and post-Wyeth level headcount

12-Nov-2015 - Pfizer’s manufacturing network would stretch beyond 100 sites if a merger deal with Allergan is reached.

Unilife undecided on takeover plans; gives December 31 deadline

10-Nov-2015 - Unilife CEO Alan Shortall yesterday confirmed the drug delivery company is still “receiving interest from several parties under the strategic review process” and set a deadline of December 31 to...

Acquisitions drive AMRI’s ambition to become a ‘billion dollar’ CDMO

09-Nov-2015 - AMRI attributed recent M&A activity to passing the $100m (€93m) quarterly sales milestone, reporting high double-digit growth across its API and small-scale manufacturing divisions.

CPhI Worldwide 2015

Rush to acquire ex-pharma sites means survival of the biggest for CMOs

22-Oct-2015 - As pharma sells off manufacturing capacity and outsources to large and specialist CMOs, smart contract houses will have an opportunity to grab market share in a currently fragmented sector, say...

CPhI Worldwide 2015

After the M&A bubble bursts: the four types of pharma firm to survive

21-Oct-2015 - An advisor to the pharma industry on M&A says the current boom in pharma valuations will not last, and R&D cost pressures will reshape firms of the future....

M&A

Sun Pharma eyes US ocular delivery expert

16-Sep-2015 - Indian generics company Sun Pharma has made a $48m (€42m) offer for US eye drug maker InSite Vision and its delivery platform.

UPDATE

Mylan targets Perrigo shareholders in latest generics mega-merger attempt

14-Sep-2015 - Mylan’s latest merger offer has been lambasted as “neither compelling, nor accretive” by Perrigo CEO Joseph Papa.

Horizon attempts $1.68bn hostile bid for Depomed

09-Sep-2015 - Horizon Pharma has renewed its efforts to take over pain and neurology firm Depomed for approximately $1.68bn (€1.5bn).

Cipla and Lannett add US plants as generics industry continues to consolidate

08-Sep-2015 - Cipla and Lannett have expanded their presence in the mid-sized US generics space through acquisitions totalling over $1.5bn.

‘Eat or be eaten;’ Mylan says Perrigo could be run as subsidiary

25-Aug-2015 - Mylan will run Perrigo as a wholly-owned subsidiary if it acquires between 50-80% of shares, the firm has clarified.

Pfizer’s $17bn Hospira deal set to close in September after US FTC clearance

24-Aug-2015 - Pfizer has received the final regulatory clearances to acquire Hospira but the US FTC says it must divests four sterile injectable products.

Merck & Co. plans over 2,500 manufacturing job cuts

17-Aug-2015 - An SEC filing reveals Merck has cut 29,160 jobs in five years, and over 2,500 more may be on the way.

Still no plans to resume manufacturing at former Ben Venue plant

17-Aug-2015 - The huge former Ben Venue injectables manufacturing plant in Ohio that became the center of controversy over drug shortages a few years ago remains off line, and the company that...

European pharma: CEO talent is the new measure of company calibre

30-Jul-2015 - Industry headhunters have picked their top CEOs in European pharma, saying the most successful investors keep chief execs in place even through hard times.  

Hikma buys B-I generics subsidiary, strengthens position in US market

28-Jul-2015 - Hikma says its $2.65bn acquisition of Roxane Laboratories will make it the sixth largest firm in the US generics space.

Update

Teva to buy Allergan's generics biz for $40.5bn

27-Jul-2015 - Teva has struck a deal to buy Allergan’s generics business a week after its persistent attempts to acquire Mylan fell through.

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...